Clinical Trials Directory

Trials / Conditions / Refractory Breast Carcinoma

Refractory Breast Carcinoma

8 registered clinical trials studyying Refractory Breast Carcinoma — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingPatient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
NCT06268652
Sun Yat-sen UniversityPhase 3
WithdrawnAbexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
NCT04498520
Pamela MunsterPhase 1
WithdrawnBreast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic
NCT04418219
Thomas Jefferson UniversityPhase 1 / Phase 2
SuspendedAlpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
NCT04120246
Veana TherapeuticsPhase 1
TerminatedNab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With
NCT04216472
M.D. Anderson Cancer CenterPhase 2
CompletedAlpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Can
NCT03207529
M.D. Anderson Cancer CenterPhase 1
TerminatedDirect Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No
NCT03432741
Mayo ClinicPhase 1
CompletedEverolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
NCT02152943
M.D. Anderson Cancer CenterPhase 1